A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

In this prospective, multicenter, phase 2 study, 64 patients with relapsed or relapsed and refractory multiple myeloma (MM) received up to 8 21-day cycles of bortezomib 1.0 mg/m(2) (days 1, 4, 8, and 11), lenalidomide 15 mg/day (days 1-14), and dexamethasone 40/20 mg/day (cycles 1-4) and 20/10 mg/da...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Richardson, Paul G., Xie, Wanling, Jagannath, Sundar, Jakubowiak, Andrzej, Lonial, Sagar, Raje, Noopur S., Alsina, Melissa, Ghobrial, Irene M., Schlossman, Robert L., Munshi, Nikhil C., Mazumder, Amitabha, Vesole, David H., Kaufman, Jonathan L., Colson, Kathleen, McKenney, Mary, Lunde, Laura E., Feather, John, Maglio, Michelle E., Warren, Diane, Francis, Dixil, Hideshima, Teru, Knight, Robert, Esseltine, Dixie-Lee, Mitsiades, Constantine S., Weller, Edie, Anderson, Kenneth C.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2014
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123434/
https://ncbi.nlm.nih.gov/pubmed/24429336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-07-517276
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars